Improving Survival Rates and Quality of Life

Early-stage lung cancer (such as carcinoma in situ or minimally invasive adenocarcinoma) has a 5-year disease-specific survival rate of up to 100% after radical surgical resection. In contrast, patients at stages IIIA to IVA have a 5-year survival rate of only 10%-36%. LDCT, as the most effective screening tool currently available, has a diagnostic accuracy exceeding 95% for tumors larger than 1 cm, significantly reducing missed diagnoses and increasing early lung cancer detection rates to 50%-70%.

Moreover, early treatment often involves minimally invasive surgery (such as thoracoscopic resection), which causes less trauma and allows faster recovery. Patients can quickly return to normal life postoperatively, greatly alleviating psychological stress and social function loss.

Reducing Medical Economic Burden

Treatment costs for advanced lung cancer are high, with annual expenses for targeted drugs and immunotherapy reaching hundreds of thousands of yuan, while early-stage surgery and postoperative rehabilitation cost only one-fifth to one-tenth of that. LDCT screening for high-risk populations helps reduce late-stage cases.

Promoting Precision Medicine and Technological Innovation

Early lung cancer screening is not only an application of imaging technology but also a reflection of multidisciplinary integration. Liquid biopsy technologies (such as ctDNA and miRNA testing), combined with radiomics, improve the accuracy in distinguishing benign and malignant nodules, reducing unnecessary biopsies or surgical risks.
Molecular characteristics (such as the high prevalence of EGFR gene mutations) provide a basis for personalized screening and treatment. Gene testing-guided early screening strategies can more precisely target high-risk populations and optimize screening efficiency.

Strengthening Public Health Awareness and Disease Prevention

1.The popularization of early lung cancer screening achieves seamless integration of
Through awareness campaigns and public welfare activities focusing on lung cancer risk factors (such as smoking, air pollution, occupational exposures), public perception has shifted from viewing lung cancer as a “terminal illness” to “preventable and controllable,” increasing willingness to participate in screening.
Early lung cancer screening is a key implementation of the “Healthy China 2030” strategy. Its significance goes beyond medicine; over the next decade, it aims to increase early lung cancer diagnosis rates to over 70%, substantially reducing mortality and truly shifting from a “disease-centered” to a “health-centered” approach.